IMMX - NASDAQ
Immix Biopharma, Inc.
$8.44
+0.90%Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
At a Glance
Live SnapshotImmix Biopharma, Inc. Management Team
Mr. Gabriel Morris B.A.
Chief Financial Officer & Director
Compensation
$712,500
Dr. Graham Ross FFPM, M.D.
Chief Medical Officer & Head of Clinical Development
Compensation
$88,593
Dr. David Marks MBBS, Ph.D.
Chief Medical Officer of Cell Therapy
Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc
Co-Founder
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Co-Founder, Chief Executive Officer & Chairman
Compensation
$712,500
Mr. Gerhard Bauer
Head of Cell Therapy Manufacturing
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.
Scientific Co-Founder
Immix Biopharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.00M and sold $633K worth of IMMX shares, resulting in $1.36M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
1.5K
10.04K
0
0.00
+10K
+$10K
6-9 Months
5.1K
10.17K
316.5K
632.91K
-623K
-$623K
9-12 Months
882.4K
1.98M
0
0.00
+2.0M
+$1.98M
Top Buyers
Morris Gabriel S
Director, Officer: Cfo
$777K
Rachman Ilya M
Director, Officer: Ceo And Chairman
$777K
Buchan Jane
Director
$74K
Chudnovsky Yekaterina
Director, 10 Percent Owner:
$74K
Ng Carey
Director
$74K
Top Sellers
Chang Nancy T
Director
$633K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.36M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
IMMX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | April 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | April 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | April 25, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.